Celltrion Reports Positive Rheumatoid Arthritis Data From Subcutaneous Infliximab
Executive Summary
New data presented by Celltrion at EULAR 2019 suggest that its subcutaneous formulation of infliximab is comparable to the intravenous version in treating rheumatoid arthritis.
You may also be interested in...
Celltrion Will Sell World's First Subcutaneous Infliximab Directly In Europe
Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.
Celltrion Will Market Subcutaneous Remsima Directly After EU Nod
Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.
Celltrion’s Subcutaneous Infliximab Shows Promise
Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.